INDICATIONS AND USAGE
AZOPT^® Suspension is a carbonic anhydrase inhibitor indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

 

DOSAGE AND ADMINISTRATION

• Instill one drop in the affected eye(s) three times daily
• If more than one topical ophthalmic drug is being used, the drugs should be administered at least ten (10) minutes apart

 

DOSAGE FORMS AND STRENGTHS

• Solution containing 10 mg/mL brinzolamide

 

IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS

• Hypersensitivity to any component of this product

 

WARNINGS AND PRECAUTIONS

• Sulfonamide hypersensitivity reactions
• Corneal edema may occur in patients with low endothelial cell counts

 

ADVERSE REACTIONS
Most common adverse reactions are blurred vision and bitter, sour or unusual taste.

 

DRUG INTERACTIONS

• There is a potential additive effect of the known systemic effects of carbonic anhydrase inhibition in patients receiving both oral and topical carbonic anhydrase inhibitors
• Rare instances of acid-base alterations have occurred with high-dose salicylate therapy

 

Before prescribing AZOPT^® Suspension, please read full prescribing information.

 

References:
1. Liu JHK, Weinreb RN. Monitoring intraocular pressure for 24 h. Br J Ophthalmol. doi:10.1136/bjo.2010.199737. 2. Bagga H, Liu JH, Weinreb RN. Intraocular pressure measurements throughout the 24 h. Curr Opin Ophthalmol. 2009;20(2):79-83. 3. Liu JHK, Zhang X, Kripke DF, Weinreb RN. Twenty-four-hour intraocular pressure pattern associated with early glaucomatous changes. Invest Ophthalmol Vis Sci. 2003;44(4):1586-1590. 4. Liu JHK, Medeiros FA, Slight JR, Weinreb RN. Comparing diurnal and nocturnal effects of brinzolamide and timolol on intraocular pressure in patients receiving latanoprost monotherapy. Ophthalmology. 2009;116(3):449-454. 5. Nakakura S, Nomura Y, Ataka S, Shiraki K. Relation between office intraocular pressure and 24-hour intraocular pressure in patients with primary open-angle glaucoma treated with a combination of topical antiglaucoma eye drops. J Glaucoma. 2007;16(2):201-204.